As U.S. President Donald Trump threatens a new round of tariffs as part of an onshoring push, Chinese President Xi Jinping is ...

Billionaire Dalio, head of the world's largest hedge fund, is considered a global authority on investing in China. The bank ...

Thousands of 3D protein structures locked up in big-pharma vaults will be used to create a new AI tool that won’t be open to ...

Obesity was tied with an increased risk of developing 16 health outcomes, a large longitudinal study showed. Risks correlated ...

AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to ...

A new medical database automatically compiles the medical records of obese patients and those suffering from obesity-related diseases in a uniquely comprehensive and reliable manner. The initiative, ...

DelveInsight’s, “Glioma Pipeline Insight, 2025” report provides comprehensive insights about 180+ companies and 200+ pipeline ...

Boehringer Ingelheim has axed development of a potential therapy for Alzheimer’s after it failed in a phase 2 trial and will focus instead on developing the drug as a treatment for schizophrenia.

Boehringer Ingelheim’s weight-loss drug candidate survodutide could also be effective for liver disease metabolic dysfunction-associated steatohepatitis (MASH), if the results of a mid-stage ...

A new medical database automatically compiles the medical records of obese patients and those suffering from obesity-related diseases in a uniquely ...

Research in mice identifies protein responsible for regulating gut movement in response to pressure, exercise, and ...

Varied approaches to remote patient monitoring are in development to close care gaps between patients and rheumatologists, ...